(Q34659804)

3 August 2017

title

Anti-melanoma effects of vorinostat in combination with polyphenolic antioxidant (-)-epigallocatechin-3-gallate (EGCG). (English)

1 reference

3 August 2017

Minakshi Nihal

1

1 reference

3 August 2017

Craig T Roelke

series ordinal

2

1 reference

3 August 2017

Gary S Wood

series ordinal

3

1 reference

3 August 2017

publication date

16 March 2010

1 reference

3 August 2017

published in

Pharmaceutical Research

1 reference

3 August 2017

volume

27

1 reference

3 August 2017

issue

6

1 reference

3 August 2017

page(s)

1103-1114

1 reference

(-)-Epigallocatechin-3-gallate (EGCG) sensitizes melanoma cells to interferon induced growth inhibition in a mouse model of human melanoma

3 August 2017

cites work

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11095-010-0054-5

Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma

21 January 2018

1 reference

12 December 2020

Prognostic significance of apoptosis regulators in breast cancer.

1 reference

12 December 2020

Histone deacetylase inhibitors in cancer therapy

1 reference

12 December 2020

Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation

1 reference

12 December 2020

Vorinostat in cutaneous T-cell lymphoma

1 reference

12 December 2020

Histone deacetylase inhibitors from microorganisms: the Astellas experience

1 reference

12 December 2020

Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large-B-cell lymphoma

1 reference

12 December 2020

Tea polyphenol (-)-epigallocatechin-3-gallate inhibits DNA methyltransferase and reactivates methylation-silenced genes in cancer cell lines.

1 reference

12 December 2020

Chemoprevention of melanoma: an unexplored strategy

1 reference

12 December 2020

What about chemoprevention for melanoma?

1 reference

12 December 2020

Histone deacetylase inhibitors and malignant melanoma.

1 reference

12 December 2020

Epigallocatechin-3-gallate, a histone acetyltransferase inhibitor, inhibits EBV-induced B lymphocyte transformation via suppression of RelA acetylation

1 reference

12 December 2020

Development of histone deacetylase inhibitors for cancer treatment

1 reference

12 December 2020

SAHA induces apoptosis in hepatoma cells and synergistically interacts with the proteasome inhibitor Bortezomib

1 reference

12 December 2020

Histone deacetylase inhibitors activate p21(WAF1) expression via ATM.

1 reference

12 December 2020

Cutaneous photoprotection and melanoma susceptibility: reaching beyond melanin content to the frontiers of DNA repair

1 reference

12 December 2020

Vorinostat, a histone deacetylase inhibitor, enhances the response of human tumor cells to ionizing radiation through prolongation of gamma-H2AX foci

1 reference

12 December 2020

Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma

1 reference

12 December 2020

Functional diversity of DNA methyltransferase inhibitors in human cancer cell lines.

1 reference

12 December 2020

Malignant melanoma: genetics and therapeutics in the genomic era.

1 reference

12 December 2020

Will histone deacetylase inhibitors require combination with other agents to fulfil their therapeutic potential?

1 reference

12 December 2020

Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in cutaneous T cell lymphoma

1 reference

12 December 2020

Combined treatment with Ad-hTRAIL and DTIC or SAHA is associated with increased mitochondrial-mediated apoptosis in human melanoma cell lines

1 reference

12 December 2020

A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study

1 reference

12 December 2020

Modulation of pro- and anti-apoptotic factors in human melanoma cells exposed to histone deacetylase inhibitors.

1 reference

12 December 2020

Activation of nuclear factor-kappa B in human metastatic melanomacells and the effect of oxidative stress

1 reference

12 December 2020

A phase 2 study of vorinostat in acute myeloid leukemia

1 reference

12 December 2020

Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma

1 reference

12 December 2020

HDAC inhibitors: clinical update and mechanism-based potential.

1 reference

12 December 2020

Meta-analysis confirms BCL2 is an independent prognostic marker in breast cancer

1 reference

12 December 2020

Anti-proliferative and proapoptotic effects of (-)-epigallocatechin-3-gallate on human melanoma: possible implications for the chemoprevention of melanoma.

1 reference

12 December 2020

Targeting events in melanoma carcinogenesis for the prevention of melanoma

1 reference

12 December 2020

Phase I trial of vorinostat and doxorubicin in solid tumours: histone deacetylase 2 expression as a predictive marker.

1 reference

12 December 2020

Reactive oxygen signaling and MAPK activation distinguish Epstein-Barr Virus (EBV)-positive versus EBV-negative Burkitt's lymphoma

1 reference

12 December 2020

Selective induction of apoptosis by histone deacetylase inhibitor SAHA in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action

1 reference

12 December 2020

Cancer chemoprevention through dietary antioxidants: progress and promise

1 reference

12 December 2020

The reactive oxygen-driven tumor: relevance to melanoma

1 reference

12 December 2020

Role of nuclear factor-kappa B in melanoma

1 reference

12 December 2020

Antitumor effect of the histone deacetylase inhibitor LAQ824 in combination with 13-cis-retinoic acid in human malignant melanoma

1 reference

12 December 2020

10.1007/S11095-010-0054-5

Identifiers

DOI

1 reference

3 August 2017

1 reference